Sclerosing cholangitis is a chronic liver disease in which the bile ducts, the tubes that carry digestive fluid (bile) from the liver to the small intestine, become inflamed, scarred, and progressively narrower. Over time, this scarring restricts bile flow, causes bile to back up in the liver, and can eventually lead to serious liver damage. The condition comes in two forms: primary sclerosing cholangitis (PSC), where no identifiable cause exists, and secondary sclerosing cholangitis (SSC), where the bile duct damage results from a known trigger like infection, blood flow problems, or toxic exposure.
Primary vs. Secondary Sclerosing Cholangitis
The distinction between primary and secondary forms matters because the causes, outlook, and cancer risks differ significantly. PSC is considered idiopathic, meaning its exact cause remains unknown. The strong link between PSC and inflammatory bowel disease (IBD) points toward an autoimmune mechanism, and current thinking is that PSC develops as a consequence of immune system activation in someone who is genetically susceptible. Roughly 60 to 80 percent of people with PSC also have IBD, most commonly ulcerative colitis.
Secondary sclerosing cholangitis, by contrast, has a clear trigger. Causes include bile duct infections, damage from reduced blood supply to the ducts, exposure to certain toxins or medications, and immune-related conditions. The prognosis for SSC is generally worse than for PSC, though outcomes depend heavily on whether the underlying cause can be treated. One important difference: PSC carries a substantially elevated risk of bile duct cancer, while most causes of SSC do not.
How the Bile Ducts Become Damaged
In PSC, the process begins with inflammation around the bile ducts. Immune cells, including lymphocytes and plasma cells, cluster most intensely near the duct walls. As the disease progresses, this active inflammation gradually subsides but leaves behind scar tissue and swelling in the surrounding tissue. The number of functional bile ducts steadily decreases.
In advanced stages, the hallmark finding is what pathologists call “onion-skin” fibrosis: concentric rings of scar tissue wrapping around medium and large bile ducts, compressing and eventually destroying the duct lining. This fibrous scarring narrows the ducts in multiple spots, creating a pattern of alternating tight segments and slightly widened segments. Bile can no longer flow freely, and the backup of bile acids damages liver cells. Left unchecked, this process leads to biliary cirrhosis, where the liver itself becomes permanently scarred and loses function.
Symptoms and How They Progress
PSC is a slow-moving disease, and many people have it for years before noticing anything wrong. A significant number of patients have no symptoms at all when they’re first diagnosed, often after routine blood work reveals abnormal liver markers.
When symptoms do appear, they typically include:
- Itchy skin (pruritus), often one of the earliest complaints
- Fatigue that doesn’t improve with rest
- Abdominal pain, usually in the upper right side
- Yellowing of the skin and eyes (jaundice)
- Fever and chills, which can signal a bile duct infection (cholangitis)
- Diarrhea
As the disease advances toward cirrhosis, additional problems develop, including fluid retention, unintentional weight loss, and worsening jaundice. Episodes of bacterial cholangitis, where bile trapped behind a narrowed duct becomes infected, can cause sudden fevers and intensifying pain.
How It’s Diagnosed
The diagnosis rests on two pillars: blood tests showing a cholestatic pattern (indicating blocked bile flow) and imaging that reveals characteristic bile duct changes. The dominant blood test finding is an elevated alkaline phosphatase level, an enzyme that rises when bile drainage is impaired. Other markers of bile flow obstruction, like GGT, are also typically elevated.
Several antibodies show up more often in PSC patients than in the general population. Atypical perinuclear antineutrophil cytoplasmic antibodies (p-ANCA) are found in 30 to 80 percent of PSC cases, and elevated immunoglobulin M levels appear in 40 to 50 percent. These aren’t definitive on their own but add supporting evidence.
The key imaging test is magnetic resonance cholangiography (MRC), a specialized type of MRI that visualizes the bile ducts without any invasive procedure. European, UK, and American guidelines all recommend it as the first-line imaging tool when PSC is suspected. On MRC, PSC produces a distinctive “beaded” appearance: short, ring-like narrowings scattered along both the intrahepatic ducts (inside the liver) and the extrahepatic ducts (outside the liver), separated by normal or slightly dilated segments. This pattern of multifocal strictures and dilations is the visual signature of the disease. Before confirming a PSC diagnosis, doctors must rule out secondary causes of bile duct scarring.
The Link to Bile Duct Cancer
One of the most serious concerns for people living with PSC is cholangiocarcinoma, or bile duct cancer. Compared to the general population, PSC patients face a 400- to 1,500-fold increased lifetime risk of developing this cancer. The estimated annual incidence is 0.5 to 1.5 percent per year, and the reported lifetime incidence reaches approximately 20 percent.
There is no universally agreed-upon screening protocol, but most large treatment centers perform yearly or every-other-year MRI or MRC scans, often combined with a blood test for a tumor marker called CA 19-9. The challenge is that cholangiocarcinoma can be difficult to distinguish from the benign strictures that PSC itself produces, which is why worsening symptoms, a rapidly rising bilirubin level, or a new stricture on imaging often prompt more direct investigation with endoscopic retrograde cholangiopancreatography (ERCP). During ERCP, doctors can obtain tissue samples by brushing the inside of the duct to check for malignant cells.
Managing Strictures and Symptoms
When a narrowing in the bile duct becomes severe enough to cause significant symptoms or lab changes, it’s called a dominant stricture. Guidelines define this as a narrowing of 1.5 mm or less in the common bile duct, or 1 mm or less in a main hepatic duct near where the two sides of the liver’s drainage system meet. These dominant strictures are the main target for endoscopic treatment.
ERCP with balloon dilation, where a small balloon is threaded into the duct and inflated to widen the narrowed area, is the primary intervention. This procedure is considered when patients develop worsening jaundice, episodes of cholangitis, increasing itchiness, or a rapid jump in liver enzymes. Symptoms that tend to improve after successful dilation include itching, pain, jaundice, and recurrent infections. In patients whose liver disease has already reached an advanced stage, the main benefit of dilation is reducing cholangitis episodes rather than reversing liver damage.
No medication has been proven to halt PSC’s progression. Some drugs can reduce alkaline phosphatase levels on blood tests, but lowering a lab number hasn’t consistently translated into better long-term outcomes or visible improvement on imaging.
Liver Transplantation and Outlook
For people whose PSC progresses to end-stage liver disease or who develop bile duct cancer, liver transplantation is the only definitive treatment. Reported five-year survival after transplant is approximately 75 percent. Transplant outcomes for PSC are generally considered favorable compared to many other liver diseases, though PSC can recur in the transplanted liver in a subset of patients.
Without transplantation, the disease follows a variable course. Some people remain stable for a decade or more with minimal symptoms, while others progress to cirrhosis within a few years of diagnosis. Declining alkaline phosphatase levels during follow-up are associated with better survival, offering one useful marker for tracking the disease’s trajectory. The strong connection to inflammatory bowel disease also means that PSC patients need regular colon cancer screening, since the combination of PSC and ulcerative colitis raises colorectal cancer risk beyond what IBD alone would cause.